National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cladribine (Mavenclad®) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features

NCPE Assessment Process Complete
Rapid review received  22/08/2017
Rapid review completed  18/09/2017
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE  03/10/2017
Pre-submission consultation with Applicant  24/10/2017
Submission received from Applicant  20/12/2017
NCPE assessment commenced 02/01/2018
Preliminary review sent to Applicant 09/02/2018
Preliminary response received from Applicant 01/03/2018
NCPE assessment re-commenced 02/03/2018
Factual accuracy sent to Applicant 18/06/2018
NCPE assessment re-commenced 02/07/2018
NCPE assessment completed 20/07/2018
NCPE assessment outcome Following NCPE assessment of the company submission, cladribine (Mavenclad®) is considered cost-effective for the treatment of adult patients with highly active relapsing MS as defined by clinical or imaging features and therefore is recommended for reimbursement.

Summary

 

The HSE has approved reimbursement following confidential price negotiations September 2018